drugset / Trial / NCT00454116

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

NCT00454116

Phase 2 Completed 106 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of 2 doses of ZACTIMA™ (ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen.

Timeline

Start
2007-03
Primary completion
2008-03
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule Oral

Indications